Insiders Are Snapping Up These 2 Stocks — and Analysts Like What They See

When looking for a clear market signal pointing toward the right stocks to buy, insiders’ trading activity remains a potent ...
TMCnet

Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in ...

Phase 3 Trial Design: The FDA agreed with Adagene’s proposed standard-of-care (SOC) control arm for the Phase 3 clinical trial and confirmed that a muzastotug monotherapy arm was also not required.

Novel nanoparticles can deliver an immune-stimulating molecule directly to ovarian tumors

Cancer immunotherapy, which uses drugs that stimulate the body's immune cells to attack tumors, is a promising approach to treating many types of cancer. However, it doesn't work well for some tumors, ...

Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC i…

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that results from the Phase III ...